LONDON (Alliance News) - Shares in Venn Life Sciences Holdings PLC were trading up 15.1% Monday morning, hovering around the top of the risers on the AIM All-Share, after it announced it had won a contract worth over EUR2.4 million for a new international study into a new heart treatment.
Under the contract the company will worth with Keith Oldroyd of the Golden Jubilee National Hospital in Scotland on the study to determine whether the use of Percutaneous Coronary Intervention with a stent using a bio-absorbable coating could be used as an effective method to treat patients with disease in the left-main coronary artery of their heart.
The study will be conducted in five European countries over two years with Oldroyd and Robert-Jan van Guens from Erasmus University in Rotterdam as the co-principal investigators.
"We are delighted to be part of this important study as it is an area of the business that we have focused on expanding in recent years. Our recent expansions and service additions allow us to supply the complete envelope of services for these studies whether they are single site or multi-country site studies," said Chief Executive Tony Richardson in a statement.
Shares in Venn were trading up 15.1% at 21.00 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
